Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
AAV-based gene therapy platform
Chimerix's_gene_therapy_assets Glybera_rights_from_the_European_Commission |
| gptkbp:CEO |
gptkb:Matthijs_P._H._H._van_der_Meer
|
| gptkbp:clinicalTrials |
gptkb:Hemophilia_B
gptkb:Fabry_disease gptkb:Huntington's_disease Phase 2 Phase 3 Phase 1/2 Gene therapy for Pompe disease Gene therapy for beta-thalassemia Gene therapy for cystic fibrosis Gene therapy for hemophilia B Gene therapy for sickle cell disease Gene therapy for spinal muscular atrophy Liver-directed gene therapy Adeno-associated_virus_gene_therapy Gene_therapy_for_Duchenne_muscular_dystrophy Gene_therapy_for_Fabry_disease Gene_therapy_for_Huntington's_disease |
| gptkbp:collaborations |
gptkb:Duke_University
gptkb:Harvard_University gptkb:University_of_Pennsylvania |
| gptkbp:employeeCount |
200+
|
| gptkbp:focus |
gene therapy
|
| gptkbp:founded |
1991
|
| gptkbp:headquarters |
Amsterdam,_Netherlands
|
| https://www.w3.org/2000/01/rdf-schema#label |
uniQure Biopharma N.V.
|
| gptkbp:investmentFocus |
$50 million Series B funding
$100 million funding round $75 million Series C funding |
| gptkbp:market |
$1.5 billion
|
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb Novartis Regenxbio |
| gptkbp:products |
gptkb:Glybera
AMT-061 AMT-130 |
| gptkbp:regulatoryCompliance |
European_Medicines_Agency_(EMA)_for_Glybera
FDA_for_AMT-061 |
| gptkbp:research_areas |
genetic disorders
rare diseases metabolic diseases |
| gptkbp:researchFocus |
gptkb:Adeno-associated_virus_(AAV)_vectors
|
| gptkbp:researchInterest |
gptkb:Lexington,_Massachusetts
Amsterdam,_Netherlands |
| gptkbp:stockSymbol |
QURE
|
| gptkbp:subsidiary |
gptkb:uniQure_N.V.
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.uniqure.com
|